2
Announcements
Trials
Browse
Landscape
Phase
Phase 1/2
1
Status
Terminated
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Lymphoid
1
Conditions
Biliary Tract Neoplasms
5
Cholangiocarcinoma
4
Lymphoma, B-Cell
2
Recurrence
1
Potentially Resectable Locally Advanced Malignant Tumors of Biliary System
1
Pancreatic Neoplasms
1
Neoplasms
1
Lymphoma, T-Cell, Peripheral
1
Lymphoma, Large B-Cell, Diffuse
1
Lymphoma, Extranodal NK-T-Cell
1
Klatskin Tumor
1
Cirrhosis, Familial, with Pulmonary Hypertension
1
Carcinoma, Transitional Cell
1
Carcinoma, Hepatocellular
1
Breast Neoplasms
1
Adenocarcinoma
1
Interventions
Cyclophosphamide
45
Prednisone
31
N-(2-amino-5-fluorobenzyl)-4-(N-(pyridine-3-acrylyl)aminomethyl)benzamide
29
Vincristine
28
Doxorubicin
27
Etoposide
22
romidepsin
20
Gemcitabine
18
Lenalidomide
16
10-propargyl-10-deazaaminopterin
16
fludarabine phosphate
15
Whole-Body Irradiation
15
Peripheral Blood Stem Cell Transplantation
14
Brentuximab Vedotin
14
Azacitidine
13
Mycophenolic Acid
12
Dexamethasone
10
Cyclosporine
10
Bortezomib
10
Alemtuzumab
10
Rituximab
8
fludarabine
7
belinostat
7
Methotrexate
6
Cytarabine
6
Busulfan
6
Bendamustine Hydrochloride
6
pembrolizumab
5
denileukin diftitox
5
Nivolumab
5
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Lymphoma, T-Cell, Peripheral
×
gemcitabine-oxaliplatin regimen
×
Clear all
NCT04425070
2026-01-05
TOUCH
Antengene Corporation
Phase 1/2
Terminated
56 enrolled